WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H317871
CAS#: 83799-24-0 (free base)
Description: Fexofenadine is an antihistamine pharmaceutical drug used in the treatment of allergy symptoms, such as hay fever, nasal congestion, and urticaria. Fexofenadine is classified as a second-generation antihistamine because it is less able to pass the blood-brain barrier and cause sedation, compared to a first-generation antihistamines.
Hodoodo Cat#: H317871
Name: Fexofenadine
CAS#: 83799-24-0 (free base)
Chemical Formula: C32H39NO4
Exact Mass: 501.29
Molecular Weight: 501.656
Elemental Analysis: C, 76.61; H, 7.84; N, 2.79; O, 12.76
Related CAS #: 83799-24-0 (free base) 153439-40-8 (HCl)
Synonym: Fexofenadine, Allegra, MDL 16.455, Telfast, Carboxyterfenadine
IUPAC/Chemical Name: 2-[4-[1-hydroxy-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butyl]phenyl]-2-methylpropanoic acid
InChi Key: RWTNPBWLLIMQHL-UHFFFAOYSA-N
InChi Code: InChI=1S/C32H39NO4/c1-31(2,30(35)36)25-17-15-24(16-18-25)29(34)14-9-21-33-22-19-28(20-23-33)32(37,26-10-5-3-6-11-26)27-12-7-4-8-13-27/h3-8,10-13,15-18,28-29,34,37H,9,14,19-23H2,1-2H3,(H,35,36)
SMILES Code: CC(C)(C1=CC=C(C(O)CCCN2CCC(C(C3=CC=CC=C3)(O)C4=CC=CC=C4)CC2)C=C1)C(O)=O
Appearance: Solid powder
Purity: >95% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | Fexofenadine (MDL-16455), a H1R antagonist, is an anti-allergic agent. |
| In vitro activity: | Fexofenadine significantly inhibited the upregulated expression of IL-8 in HCT116 and COLO205 cells stimulated with TNF-α. Fexofenadine suppressed nuclear factor-κB DNA-binding activity. Reference: J Pharmacol Exp Ther. 2015 Mar;352(3):455-61. https://pubmed.ncbi.nlm.nih.gov/25538104/ |
| In vivo activity: | This study investigated inhibition of the immune response in palladium allergic mice by administration of prednisolone as a glucocorticoid and fexofenadine hydrochloride as an antihistamine. Compared with glucocorticoids, fexofenadine hydrochloride significantly suppressed the number of T cells by interfering with the development of antigen-presenting cells from the sensitization phase. Reference: Int J Mol Sci. 2017 Jun 25;18(7):1357. https://pubmed.ncbi.nlm.nih.gov/28672829/ |
The following data is based on the product molecular weight 501.66 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | 1. Liu R, Chen Y, Fu W, Wang S, Cui Y, Zhao X, Lei ZN, Hettinghouse A, Liu J, Wang C, Zhang C, Bi Y, Xiao G, Chen ZS, Liu CJ. Fexofenadine inhibits TNF signaling through targeting to cytosolic phospholipase A2 and is therapeutic against inflammatory arthritis. Ann Rheum Dis. 2019 Nov;78(11):1524-1535. doi: 10.1136/annrheumdis-2019-215543. Epub 2019 Jul 13. PMID: 31302596; PMCID: PMC8157820. 2. Koh SJ, Kim JW, Kim BG, Lee KL, Chun J, Kim JS. Fexofenadine regulates nuclear factor-κB signaling and endoplasmic reticulum stress in intestinal epithelial cells and ameliorates acute and chronic colitis in mice. J Pharmacol Exp Ther. 2015 Mar;352(3):455-61. doi: 10.1124/jpet.114.217844. Epub 2014 Dec 23. PMID: 25538104. 3. Matsubara R, Kumagai K, Shigematsu H, Kitaura K, Nakasone Y, Suzuki S, Hamada Y, Suzuki R. Fexofenadine Suppresses Delayed-Type Hypersensitivity in the Murine Model of Palladium Allergy. Int J Mol Sci. 2017 Jun 25;18(7):1357. doi: 10.3390/ijms18071357. PMID: 28672829; PMCID: PMC5535850. |
| In vitro protocol: | 1. Liu R, Chen Y, Fu W, Wang S, Cui Y, Zhao X, Lei ZN, Hettinghouse A, Liu J, Wang C, Zhang C, Bi Y, Xiao G, Chen ZS, Liu CJ. Fexofenadine inhibits TNF signaling through targeting to cytosolic phospholipase A2 and is therapeutic against inflammatory arthritis. Ann Rheum Dis. 2019 Nov;78(11):1524-1535. doi: 10.1136/annrheumdis-2019-215543. Epub 2019 Jul 13. PMID: 31302596; PMCID: PMC8157820. 2. Koh SJ, Kim JW, Kim BG, Lee KL, Chun J, Kim JS. Fexofenadine regulates nuclear factor-κB signaling and endoplasmic reticulum stress in intestinal epithelial cells and ameliorates acute and chronic colitis in mice. J Pharmacol Exp Ther. 2015 Mar;352(3):455-61. doi: 10.1124/jpet.114.217844. Epub 2014 Dec 23. PMID: 25538104. |
| In vivo protocol: | 1. Liu R, Chen Y, Fu W, Wang S, Cui Y, Zhao X, Lei ZN, Hettinghouse A, Liu J, Wang C, Zhang C, Bi Y, Xiao G, Chen ZS, Liu CJ. Fexofenadine inhibits TNF signaling through targeting to cytosolic phospholipase A2 and is therapeutic against inflammatory arthritis. Ann Rheum Dis. 2019 Nov;78(11):1524-1535. doi: 10.1136/annrheumdis-2019-215543. Epub 2019 Jul 13. PMID: 31302596; PMCID: PMC8157820. 2. Matsubara R, Kumagai K, Shigematsu H, Kitaura K, Nakasone Y, Suzuki S, Hamada Y, Suzuki R. Fexofenadine Suppresses Delayed-Type Hypersensitivity in the Murine Model of Palladium Allergy. Int J Mol Sci. 2017 Jun 25;18(7):1357. doi: 10.3390/ijms18071357. PMID: 28672829; PMCID: PMC5535850. |
1: Yao M, Srinivas NR. Quantification of fexofenadine in biological matrices: a review of bioanalytical methods. Biomed Chromatogr. 2012 Aug;26(8):942-61. doi: 10.1002/bmc.2712. Epub 2012 Feb 21. Review. PubMed PMID: 22354834.
2: Compalati E, Baena-Cagnani R, Penagos M, Badellino H, Braido F, Gómez RM, Canonica GW, Baena-Cagnani CE. Systematic review on the efficacy of fexofenadine in seasonal allergic rhinitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials. Int Arch Allergy Immunol. 2011;156(1):1-15. Review. PubMed PMID: 21969990.
3: Miura M, Uno T. Clinical pharmacokinetics of fexofenadine enantiomers. Expert Opin Drug Metab Toxicol. 2010 Jan;6(1):69-74. doi: 10.1517/17425250903382615. Review. PubMed PMID: 19947891.
4: Smith SM, Gums JG. Fexofenadine: biochemical, pharmacokinetic and pharmacodynamic properties and its unique role in allergic disorders. Expert Opin Drug Metab Toxicol. 2009 Jul;5(7):813-22. doi: 10.1517/17425250903044967. Review. PubMed PMID: 19545214.
5: Bachert C. A review of the efficacy of desloratadine, fexofenadine, and levocetirizine in the treatment of nasal congestion in patients with allergic rhinitis. Clin Ther. 2009 May;31(5):921-44. doi: 10.1016/j.clinthera.2009.05.017. Review. PubMed PMID: 19539095.
6: Devillier P, Roche N, Faisy C. Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review. Clin Pharmacokinet. 2008;47(4):217-30. Review. PubMed PMID: 18336052.
7: Mansfield LE. Fexofenadine in pediatrics: oral tablet and suspension formulations. Expert Opin Pharmacother. 2008 Feb;9(2):329-37. doi: 10.1517/14656566.9.2.329 . Review. PubMed PMID: 18201155.
8: Chen C. Some pharmacokinetic aspects of the lipophilic terfenadine and zwitterionic fexofenadine in humans. Drugs R D. 2007;8(5):301-14. Review. PubMed PMID: 17767395.
9: Mansfield LE. Once-daily immediate-release fexofenadine and sustained-release pseudoephedrine combination: a new treatment option for allergic rhinitis. Expert Opin Pharmacother. 2006 May;7(7):941-51. Review. PubMed PMID: 16634716.
10: Molimard M, Diquet B, Benedetti MS. Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Fundam Clin Pharmacol. 2004 Aug;18(4):399-411. Review. PubMed PMID: 15312146.
11: Ciprandi G, Tosca MA, Cosentino C, Riccio AM, Passalacqua G, Canonica GW. Effects of fexofenadine and other antihistamines on components of the allergic response: adhesion molecules. J Allergy Clin Immunol. 2003 Oct;112(4 Suppl):S78-82. Review. PubMed PMID: 14530792.
12: Meeves SG, Appajosyula S. Efficacy and safety profile of fexofenadine HCl: a unique therapeutic option in H1-receptor antagonist treatment. J Allergy Clin Immunol. 2003 Oct;112(4 Suppl):S69-77. Review. PubMed PMID: 14530791.
13: Kawashima M, Harada S, Tango T. Review of fexofenadine in the treatment of chronic idiopathic urticaria. Int J Dermatol. 2002 Oct;41(10):701-6. Review. PubMed PMID: 12390200.
14: Amichai B, Grunwald MH, Brenner L. Fexofenadine hydrochloride--a new anti-histaminic drug. Isr Med Assoc J. 2001 Mar;3(3):207-9. Review. PubMed PMID: 11303380.
15: Mason J, Reynolds R, Rao N. The systemic safety of fexofenadine HCl. Clin Exp Allergy. 1999 Jul;29 Suppl 3:163-70; discussion 171-3. Review. PubMed PMID: 10444232.
16: Pratt CM, Mason J, Russell T, Reynolds R, Ahlbrandt R. Cardiovascular safety of fexofenadine HCl. Am J Cardiol. 1999 May 15;83(10):1451-4. Review. PubMed PMID: 10335761.
17: Markham A, Wagstaff AJ. Fexofenadine. Drugs. 1998 Feb;55(2):269-74; discussion 275-6. Review. PubMed PMID: 9506246.
